SIMPATHIC Drug Repurposing Project
Euro-DyMA have officially commenced work as an official patient organisation on the huge EC HORIZON SIMPATHIC project for drug repurposing.
SIMPATHIC aims to accelerate drug approval by looking into rare diseases with different genetic causes but similar symptoms and common molecular processes. Simultaneous development of drugs across conditions with collaboration between patient groups, researchers, clinicians and other stakeholders should lead to robust processes, training procedures, regulatory dossiers and, ultimately, novel treatments and a model to apply to other conditions.